• Scientifc Lead Sandor Kantor has a speaker slot at the CNS Therapeutics Xchange on 26th May see conference page for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent
  • the effectiveness of a clinically relevant dose of ketamine...
  • Head to 2021 conferences page to see titles of abstracts...
 

Mismatch Negativity

Mismatch Negativity (MMN) is studied within the field of cognitive neuroscience and psychology.

What is Mismatch negativity?

mismatch negativity We've applied our expertise in EEG to develop rodent mismatch negativity (MMN) - regarded as one of the most highly-translatable biomarkers for schizophrenia. MMN is a human scalp recorded event related potential (ERP) component evoked by a sound which deviates from a repeating pattern of recent sounds. MMN is generated by a temporo-frontal network including the auditory cortex and is known to be diminished in schizophrenic patients. This disruption can be mimicked by NMDA antagonists (e.g. ketamine) treatment in healthy volunteers. Via collaborations with Cadent and Lundbeck, we have thoroughly validated our MMN protocols with NMDA antagonists such as MK-801, PCP and ketamine in rodents using in-vivo EEG, demonstrating the utility of MMN as a potential translational marker for novel treatments for schizophrenia.

MMN Preclinical Research at Transpharmation

Whether you are interested in Mismatch Negativity, pain models, sleep models or anything in between, please don’t hesitate to contact us. We are committed to offering on-time data delivery and offering flexibility in dealing with and structuring your project. To achieve this we will work alongside you in collaborative research, via contract work or in a full-time capacity - wherever you are around the globe.

Our elegant electrophysiological approach enables detection of translational ERP endpoints such as N1 and MMN-like responses in standard and oddball paradigm stimuli in response to test compounds, benchmarked against NMDA antagonists, (ketamine, MK-801, PCP). Furthermore, our battery of rodent cognition tests provides the opportunity for assessing whether NCEs have the potential utility for treating a range of cognitive impairments associated with schizophrenia compared to atypical antipsychotics such as clozapine.


mismatch negativity This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here or to get your project underway please do contact us.

 

Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk


Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design